|Mr. David L. Lucchino||Co-Founder, Pres, CEO & Director||1.1M||N/A||1969|
|Mr. Peter P. Pfreundschuh||Chief Financial Officer||535k||N/A||1969|
|Ms. Wendy S. Arnold||Chief People Officer||550.37k||N/A||1972|
|Dr. Christopher R. Loose||CoÂ-Founder & Chief Scientific Officer||N/A||N/A||1981|
|Mr. William J. McLean||Co-ÂFounder and VP of Biology & Regenerative Medicine||N/A||N/A||N/A|
|Mr. Richard J. Mitrano||VP of Fin. & Operations||N/A||N/A||1970|
|Dr. Jeff Hrkach||Sr. VP of Technology Devel.||N/A||N/A||1966|
|Mr. Michael D. Bookman J.D.||Gen. Counsel & Sec.||N/A||N/A||1987|
|Dr. Dana C. Hilt||Chief Medical Officer||N/A||N/A||1953|
|Dr. Carl P. LeBel||Chief Devel. Officer||N/A||N/A||1959|
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Woburn, Massachusetts.
Frequency Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2021 is 8. The pillar scores are Audit: 4; Board: 8; Shareholder rights: 8; Compensation: 9.